Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels

Abstract Background and Aims Regorafenib has demonstrated its survival benefit for unresectable hepatocellular carcinoma (uHCC) patients in a phase III clinical trial. We aimed to assess the efficacy and tolerability of regorafenib and the predictors of treatment outcomes in Taiwanese patients. Meth...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Po‐Yao Hsu, Tzu‐Sheng Cheng, Shih‐Chang Chuang, Wen‐Tsan Chang, Po‐Cheng Liang, Cheng‐Ting Hsu, Yu‐Ju Wei, Tyng‐Yuan Jang, Ming‐Lun Yeh, Ching‐I Huang, Yi‐Hung Lin, Chih‐Wen Wang, Ming‐Yen Hsieh, Nai‐Jen Hou, Meng‐Hsuan Hsieh, Yi‐Shan Tsai, Yu‐Min Ko, Ching‐Chih Lin, Kuan‐Yu Chen, Chia‐Yen Dai, Zu‐Yau Lin, Shinn‐Cherng Chen, Jee‐Fu Huang, Wan‐Long Chuang, Chung‐Feng Huang, Ming‐Lung Yu
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Wiley 2022-01-01
Schriftenreihe:	Cancer Medicine
Schlagworte:	efficacy hepatocellular carcinoma regorafenib sorafenib
Online-Zugang:	https://doi.org/10.1002/cam4.4430
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!